Newsroom

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities of XTI Aerospace, Inc. (NASDAQ: XTIA) between April 15, 2026 and August 17, 2026. XTI Aerospace describes itself as an “aerospace and advanced technology company.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that XTI Aerospace, Inc. (NAS...

CAMARILLO, Calif.--(BUSINESS WIRE)--Teledyne Space Imaging, a leading supplier of space-qualified imaging sensors, focal plane arrays, and integrated camera systems, celebrated a major milestone following the successful launch of NASA's Nancy Grace Roman Space Telescope, which lifted off on August 30 aboard a SpaceX Falcon Heavy rocket from Kennedy Space Center in Florida. With the launch of Roman, there are now more than 1,000 Teledyne scientific imaging sensors in space, including those aboar...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日公布第三期HERIZON-GEA-01試驗第二次期中分析(IA2)的積極初步主要結果。該試驗旨在評估ZIIHERA® (zanidatamab)聯合化療（加用和不加用TEVIMBRA® (tislelizumab)）用於一線治療人類表皮生長因子受體2陽性(HER2+)局部晚期或轉移性胃食管腺癌(GEA)的療效。在IA2中，相較於trastuzumab聯合化療，ZIIHERA聯合化療在整體存活期(OS)方面展現出具有統計學顯著性和臨床意義的改善，達到了本研究剩餘的主要終點分析。 IA2同時為TEVIMBRA聯合ZIIHERA及化療方案提供了更長隨訪期的資料，顯示出改善的OS風險比、持續的療效以及整體可控的安全性特徵。這些結果進一步印證了IA1的發現——該方案達到了無惡化存活期(PFS)和OS終點，且在PD-L1和HER2陽性表達水準中均觀察到整體存活期獲益。 BeOne Medic...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, heeft vandaag positieve hoofdresultaten bekendgemaakt van de tweede tussentijdse analyse (IA2) van de Fase 3-studie HERIZON-GEA-01. In deze studie wordt ZIIHERA® (zanidatamab) onderzocht in combinatie met chemotherapie, al dan niet aangevuld met TEVIMBRA® (tislelizumab), als eerstelijnsbehandeling voor HER2-positief, lokaal gevorderd of gemetastaseerd gastro-oesofa...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una empresa global de oncología, anunció hoy resultados positivos del segundo análisis interino (IA2) del ensayo de fase 3 HERIZON-GEA-01, que evalúa ZIIHERA® (zanidatamab), en combinación con quimioterapia, con y sin TEVIMBRA® (tislelizumab), como tratamiento de primera línea para pacientes con adenocarcinoma gastroesofágico (GEA) HER2+ localmente avanzado o metastásico. En el IA2, la combina...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute positive Topline-Ergebnisse der zweiten Zwischenanalyse (IA2) der Phase-3-Studie HERIZON-GEA-01 bekannt, in der ZIIHERA® (Zanidatamab) in Kombination mit einer Chemotherapie, mit und ohne TEVIMBRA® (Tislelizumab), als Erstlinienbehandlung bei HER2-positivem lokal fortgeschrittenem oder metastasiertem gastroösophagealem Adenokarzinom (GEA) u...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société internationale spécialisée en oncologie, a annoncé aujourd’hui les premiers résultats positifs de la deuxième analyse intermédiaire (IA2) de l’essai de phase III HERIZON-GEA-01 évaluant le ZIIHERA® (zanidatamab), en association avec une chimiothérapie, avec ou sans TEVIMBRA® en tant que traitement de première intention de l’adénocarcinome gastro-œsophagien (GEA) HER2+ localement a...

CLEARWATER, Fla.--(BUSINESS WIRE)--Churchill Stateside Group, LLC (“CSG”), a real estate and renewable energy financial services company, is pleased to announce the closing of financing for the acquisition and rehabilitation of an eight-property USDA Rural Development (“USDA RD”) 515 portfolio totaling 202 units across Fallon and Lovelock, Nevada. The financing includes a $9,600,000 Tax Exempt Equity Bridge Loan provided by Churchill Mortgage Capital (“CMC”) and a $19,520,000 USDA RD 538 Option...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Super Micro Computer, Inc. (“Super Micro” or the “Company”) (NasdaqGS: SMCI).On March 19, 2026, post-market, the U.S. Department of Justice announced the unsealing of an indictment against three individuals associated with the Company, Yih-Shyan Liaw (the Company’s co-foun...

CHICAGO--(BUSINESS WIRE)--Business travel doesn't end when the workday does. New research commissioned by Hyatt finds that 90% of business travelers say their hotel room is the only place they truly feel "off the clock" during a work trip. Nearly half (47%) would rather spend free time relaxing alone in their room than attending optional networking events. And some travelers are going to creative lengths to protect that time – including blocking fake meetings on their calendars or inventing exc...